Breaking News Bar

Business News and Information

Shandong Luoxin Acquires Constipation Drug in $68 Million Agreement

Shandong Luoxin Pharma signed a $68 million agreement to acquire greater China rights to Trulance® (plecanatide) from Synergy Pharma of the US . Trulance treats chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation. Luoxin will make a $12 million upfront payment and will be responsible for an additional $56 million of regulatory and sales milestones, plus royalties. In China , Luoxin offers products for needs in the gastrointestinal, respiratory, cardiovascular, infectious and cancer disease sectors. More details.... Stock Symbol: (NSDQ: SGYP) Share this with colleagues: // //
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear